Clinical Trials Browser

Phase 2/3 × ibrutinib × Other hematologic neoplasm × Clear all

NCT02801578 2020-02-27

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 2/3 Completed

11 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03642236 2018-08-22

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Phase 2/3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute